{"id":5232,"date":"2026-05-13T20:00:00","date_gmt":"2026-05-13T18:00:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=98aa5306515babbd590423d4e170a4d8"},"modified":"2026-05-13T20:00:00","modified_gmt":"2026-05-13T18:00:00","slug":"facet-life-sciences-evolves-leadership-structure-to-strengthen-product-pathmaking-solutions-deepen-partnership-value","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=5232","title":{"rendered":"Facet Life Sciences Evolves Leadership Structure to Strengthen Product Pathmaking Solutions &amp; Deepen Partnership Value"},"content":{"rendered":"<p>WAYNE, Pa.--(BUSINESS WIRE)--To support continued growth, <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffacetlifesciences.com%2F&amp;esheet=54533920&amp;newsitemid=20260513644823&amp;lan=en-US&amp;anchor=Facet+Life+Sciences&amp;index=1&amp;md5=018bf6f3d97a9e6715f15d1a6fd484d3\" rel=\"nofollow\" shape=\"rect\">Facet Life Sciences<\/a>, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, today announced executive team changes. Facet helps lean science teams navigate FDA approval and commercialization in complex, high-risk markets. This growth reflects a strengthened commitment to providing clarity, direction, and stability to accelerate our clients\u2019 programs with confidence. Transitions will take effect between Q2 and Q3 2026.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260513644823\/en\/2802129\/5\/facets_LS_final_for_web.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260513644823\/en\/2802129\/22\/facets_LS_final_for_web.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260513644823\/en\/2802129\/5\/facets_LS_final_for_web.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260513644823\/en\/2802129\/21\/facets_LS_final_for_web.jpg\" \/><\/a><ul class=\"bwlistdisc\">\n<li>\n<b>Tom Hallam<\/b>, Ph.D., MBA, will serve as Facet\u2019s President and Chief Operating Officer, while <b>Lane Jaeckle Santos<\/b>, Ph.D., RAC, assumes the role of Strategic Program Champion and Regulatory Services Team Manager.<\/li>\n<li>\n<b>Lisa Jenkins VanLuvanee<\/b>, Ph.D., steps up as Facet\u2019s first Chief Values Officer.<\/li>\n<li>\n<b>Ken VanLuvanee<\/b> will maintain his roles as Facet\u2019s CEO &amp; Board Chairman to maximize the company\u2019s position as a trusted advisor to developers seeking a feasible path to and through the FDA.<\/li>\n<\/ul><p>\n\u201cThis is an exciting time for Facet,\u201d says Ken VanLuvanee, CEO. \u201cOur clear-eyed focus has always been on creating and executing development strategies for emerging life sciences companies. By expanding and empowering our executive team, we position Facet exactly where our customers need us to be \u2014 a growing company with strong leadership, positioned to deliver for them now and into the future.\u201d<\/p><p>\n\"We are entering this next chapter with a clear focus on delivering meaningful impact for our clients,\u201d says Tom Hallam, Ph.D., MBA, President &amp; COO. \"At Facet, we bring experience and judgment to complex decision-making environments, and that remains core to who we are. These leadership updates position us to deliver that impact with greater consistency and scale.\"<\/p><p>\n\u201cBecoming Facet's first Chief Values Officer is an honor that reflects everything this team has built over the past 14 years,\u201d says Lisa Jenkins VanLuvanee, Ph.D., CVO. \u201cMy focus is on cultivating the mindset and culture required to operate at the frontier of innovation \u2014 one defined by intellectual courage, analytical discipline, and the strategic judgment to guide clients and colleagues through uncharted territory.\u201d<\/p><p>\nThese changes represent Facet\u2019s expanded capacity and an era of improved collaboration across our expert teams, both internally and with our dedicated scientific partners.<\/p><p>\n<b>About Facet Life Sciences<\/b><\/p><p>\nFacet Life Sciences supports emerging life sciences companies looking for feasible pathways to and through the FDA. With deep expertise across therapeutic applications, Facet provides regulatory strategy, FDA submission leadership, gap analysis, regulatory writing services, commercial strategy, and more. The multidisciplinary team of experts helps innovators navigate regulatory complexity and build cost-conscious programs designed for both FDA approval and real-world success.<\/p><p>\nFollow Facet Life Sciences on LinkedIn: <a  href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ffacet-life-sciences&amp;esheet=54533920&amp;newsitemid=20260513644823&amp;lan=en-US&amp;anchor=linkedin.com%2Fcompany%2Ffacet-life-sciences&amp;index=2&amp;md5=7d4326affc08c52f78a82a3554085605\" rel=\"nofollow\" shape=\"rect\">linkedin.com\/company\/facet-life-sciences<\/a><\/p><br\/> <b>Contacts<\/b> <br\/><p>\nTom Hallam, Ph.D., MBA\n<br\/>President &amp; COO\n<br\/><a  href=\"mailto:tom.hallam@facetls.com\" rel=\"nofollow\" shape=\"rect\">tom.hallam@facetls.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa.&#8211;(BUSINESS WIRE)&#8211;To support continued growth, Facet Life Sciences, a product pathmaker for emerging biotechnology, pharmaceutical, and device developers, today announced executive team changes. Facet helps lean science teams navigate FDA ap&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5232","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5232"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5232\/revisions"}],"predecessor-version":[{"id":5233,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/5232\/revisions\/5233"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}